BIOLOGY AND CONTROL OF LYME DISEASE BORRELIA

莱姆病疏螺旋体的生物学和控制

• 批准号: 6510576
• 负责人: Alan G. Barbour
• 金额: $ 29.19万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 2005-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6510576
• 关键词: Borrelia; Lyme disease; antibacterial antibody; antigen antibody reaction; bacterial antigens; bacterial vaccines; bactericidal immunity; communicable disease control; evolution; field study; host organism interaction; human subject; laboratory mouse; opsonin; population genetics; protein structure function; vaccine development

DESCRIPTION (Adapted from Applicant's Abstract): The proposed collaborative project is based collectively on investigations of the pathogenesis and epidemiology of Lyme disease, the ecology, vector biology, and population genetics of vector-borne diseases, the molecular biology of Borrelia burgdorferi, and vaccine development. The emphases of the proposed studies are the evolutionary biology of B. burgdorferi and new strategies for Lyme disease prevention. The long term goals are the following: (1) To significantly reduce the risk of Lyme disease among humans and domestic animals by vaccine intervention in the natural maintenance cycle of B. burgdorferi in a highly endemic area. (2) To study the evolution of B. burgdorferi as an infectious agent through controlled intervention studies in a highly endemic area. (3)To provide for a vaccine that is highly effective and that can be expeditiously, safely, and inexpensively administered in the field. The hypotheses for the project are the following: (A) A high prevalence of anti-OspA antibodies among Peromyscus leucopus and/or other mammalian reservoirs in the field will reduce the transmission rate between reservoir hosts and vector ticks, thereby reducing the prevalence of B. burgdorferi infection in ticks. (B) Immunization of reservoirs in the field will not alter the population structure of B. burgdorferi at the vaccine field sites in comparison to the control sites. (C) Transmission-blocking immunity among P. leucopus and/or other mammalian reservoirs can be achieved by oral as well as by parenteral immunization with a single immunogen or combined immunogens. The specific aims are the following: (1) Field studies of the effect of immunization of P. leucopus on the rate of transmission of B. burgdorferi between reservoir host and vector ticks. (2) Assessment of the effects of vaccine intervention in the field on the population structure of B. burgdorferi in ticks and in vertebrate reservoirs. (3) Further development of single-vaccination and orally-delivered field vaccines and evaluation of second, supplementary antigens. The proposed studies may provide insights as molecular, organismal, and population levels about B. burgdorferi, its transmission, and reservoir host immunize responses. The results may also have relevance for the control of other vector-bone zoonotic diseases and perhaps for development of novel methods for vaccine delivery.

描述（改编自申请人的摘要）：拟议的合作 该项目共同基于发病机制的研究和 莱姆病的流行病学、生态学、媒介生物学和人口 媒介传播疾病的遗传学、疏螺旋体的分子生物学 伯氏杆菌和疫苗开发。拟议研究的重点是 伯氏疏螺旋体的进化生物学和莱姆病的新策略 预防。 长期目标如下： (1) 显着降低风险 通过疫苗干预在人类和家畜中传播莱姆病 伯氏疏螺旋体在高流行地区的自然维持周期。 (2) 至 通过受控研究伯氏疏螺旋体作为传染原的进化 高流行地区的干预研究。 (3) 提供疫苗 非常有效，并且可以快速、安全且廉价 进行实地管理。 该项目的假设如下： (A) 白白鼠和/或其他哺乳动物中的抗 OspA 抗体 油田内的水库会降低水库之间的传输率 宿主和媒介蜱，从而减少伯氏疏螺旋体的流行 蜱虫感染。 (B) 现场水库免疫不会改变 伯氏疏螺旋体在疫苗接种点的种群结构 与对照位点的比较。 (C) P 中的传播阻断免疫力。 白细胞和/或其他哺乳动物储存库可以通过口服和口服获得 通过用单一免疫原或组合免疫原进行肠胃外免疫。 具体目标如下： (1) 实地考察效果 P. leucopus 免疫对伯氏疏螺旋体传播率的影响 储存宿主和媒介蜱之间。 (2) 效果评估 现场疫苗干预对伯氏疏螺旋体种群结构的影响 在蜱虫和脊椎动物储存库中。 （三）进一步发展 单次接种和口服野疫苗及其评价 第二，补充抗原。 拟议的研究可能会提供分子、有机体和 伯氏疏螺旋体的种群水平、其传播和储存宿主 免疫反应。结果也可能与控制相关 其他媒介骨人畜共患疾病，或许还可以用于开发新的 疫苗递送方法。